Igenomix UK Revenue and Competitors

Guildford,

Location

N/A

Total Funding

Analytics

Industry

Estimated Revenue & Valuation

  • Igenomix UK's estimated annual revenue is currently $1.2M per year.(i)
  • Igenomix UK's estimated revenue per employee is $84,000

Employee Data

  • Igenomix UK has 14 Employees.(i)
  • Igenomix UK grew their employee count by -18% last year.

Igenomix UK's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12.6M90-36%$14.1MN/A
#2
$83.2M468-3%$251MN/A
#3
$14M1001%N/AN/A
#4
$14.6M0N/A$12.5MN/A
#5
$30.3M197-6%N/AN/A
#6
$0.1M6-25%$2.6MN/A
#7
$45.1M2932%N/AN/A
#8
$4.8M43-7%N/AN/A
#9
$399.3M203740%N/AN/A
#10
$44M2864%N/AN/A
Add Company

What Is Igenomix UK?

IGENOMIX UK provides advanced services in reproductive genetics. Our broad experience and strong history of research & development make us one of the global leaders in this field. We use cutting-edge technology to provide the best services, from embryo testing (PGS/PGD), endometrial receptivity and microbiome analysis (ERA, EMMA, ALICE), to carrier screening (CGT) and our very highly-regarded non-invasive prenatal test (NACE).

keywords:N/A

N/A

Total Funding

14

Number of Employees

$1.2M

Revenue (est)

-18%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Igenomix UK News

2022-04-20 - Non-Invasive Prenatal Testing Market: Detailed analysis of ...

... Eurofins LifeCodexx GmbH., IGENOMIX INDIA, 10x Genomics, NIPD Genetics, Progenity, Inc., Invitae Corporation, ... UK: +44 208 089 1725.

2022-04-17 - Non-invasive Prenatal Testing Market to Reach US$ 5.1 Bn by ...

... especially in developed countries such as U.S., U.K., France, Germany, ... INC., PerkinElmer Inc, Eurofins LifeCodexx AG, and IGENOMIX.

2022-04-13 - Oil-based versus water-based contrast media for ...

KNMP.nl) and the NICE British National Formulary (www.bnf.nice.org.uk). ... consultancy for ObsEva, Merck, Merck KGaA, iGenomix and Guerbet.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.7M14N/AN/A
#2
$1.1M14-7%N/A
#3
$3.1M16N/AN/A
#4
$2.1M17N/AN/A
#5
$3.5M190%N/A